{
    "ticker": "CTMX",
    "name": "CytomX Therapeutics, Inc.",
    "description": "CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative antibody therapeutics for the treatment of cancer. Founded in 2011, CytomX is recognized for its proprietary Probody\u2122 platform technology that enables the creation of masked antibodies that selectively activate in the tumor microenvironment, minimizing effects on healthy tissues. The company\u2019s approach aims to improve the efficacy and safety of cancer therapies, addressing the significant need for more targeted treatments. CytomX has several product candidates in clinical trials, including therapies designed to treat various types of solid tumors and hematologic malignancies. The company collaborates with leading pharmaceutical companies to expand its pipeline and leverage its technology for the development of next-generation immuno-oncology therapies. With a focus on transforming cancer treatment through innovative science, CytomX Therapeutics is committed to delivering meaningful improvements in patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2011",
    "website": "https://www.cytomx.com",
    "ceo": "Sean McCarthy, Ph.D.",
    "social_media": {
        "twitter": "https://twitter.com/CytomX",
        "linkedin": "https://www.linkedin.com/company/cytomx-therapeutics/"
    },
    "investor_relations": "https://investors.cytomx.com",
    "key_executives": [
        {
            "name": "Sean McCarthy, Ph.D.",
            "position": "CEO"
        },
        {
            "name": "Jennifer W. Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Probody Therapeutics",
            "products": [
                "CX-072",
                "CX-2009",
                "CX-2029"
            ]
        }
    ],
    "seo": {
        "meta_title": "CytomX Therapeutics, Inc. | Innovative Cancer Treatment Solutions",
        "meta_description": "Explore CytomX Therapeutics, Inc., a leader in developing Probody therapeutics for cancer treatment. Learn about their innovative approach and pipeline.",
        "keywords": [
            "CytomX",
            "Probody",
            "Cancer Treatment",
            "Biotechnology",
            "Immuno-Oncology"
        ]
    },
    "faq": [
        {
            "question": "What is CytomX Therapeutics known for?",
            "answer": "CytomX Therapeutics is known for its innovative Probody platform that enables targeted cancer therapies."
        },
        {
            "question": "Who is the CEO of CytomX?",
            "answer": "Sean McCarthy, Ph.D. is the CEO of CytomX Therapeutics, Inc."
        },
        {
            "question": "Where is CytomX headquartered?",
            "answer": "CytomX is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are CytomX's main products?",
            "answer": "CytomX's main products include CX-072, CX-2009, and CX-2029."
        },
        {
            "question": "When was CytomX founded?",
            "answer": "CytomX was founded in 2011."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "PCVX"
    ],
    "related_stocks": [
        "BMY",
        "AVEO",
        "MRNA",
        "PFE"
    ]
}